Vertaling van "availability of products " (Nederlands → Frans) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat barbituraat bevat
produit contenant du barbiturique

product dat baricitinib bevat
produit contenant du baricitinib

IN-CONTEXT TRANSLATIONS

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

It is important that the most promising products are identified so that available means (such as time, trial animals, working time, money) can quickly be concentrated on further development of these products.
It is important that the most promising products are identified so that available means (such as time, trial animals, working time, money) can quickly be concentrated on further development of these products.

Het CVMP heeft zijn standpuntnota met betrekking tot de beschikbaarheid van producten voor minder belangrijke indicaties en diersoorten (Position paper regarding availability of products for minor uses and minor species - EMEA/CVMP/477/03/final) vastgesteld, waarin uitvoerig de strategie wordt beschreven die gevolgd moet worden om een grotere beschikbaarheid van geneesmiddelen in de veterinaire sector te bewerkstelligen.
Le CVMP a adopté son «Document de position relatif à la disponibilité des médicaments destinés à des utilisations mineures et à des espèces mineures« (EMEA/CVMP/477/03/final) qui détaille la stratégie à adopter pour progresser dans la voie d'une plus grande disponibilité des médicaments dans le secteur vétérinaire.

The extensive Phase III program for this product has demonstrated statistically superior improvements in lung function and COPD symptoms, especially breathlessness, compared to currently available bronchodilators, including the market leader tiotropium.
Le vaste programme de phase III pour ce produit a apporté, par comparaison avec les bronchodilatateurs courants, dont tiotropium le leader du marché, la preuve d’améliorations plus importantes de la fonction pulmonaire et des symptômes de la BPCO, en particulier concernant l’essoufflement.

In short, we are working to gain your confidence, to help us oversee the safety, quality and efficacy of the available medicines and health products.
In short, we are working to gain your confidence, to help us oversee the safety, quality and efficacy of the available medicines and health products.

A few years later, the same SCF published an additional report that was triggered by the fact that the firm which produces “Red Bull” had made available further information and experimental data concerning the product.
Le même SCF a publié quelques années plus tard un rapport complémentaire suite à l’envoi par le principal fabriquant de ces boissons d’autres informations et données expérimentales sur le produit et suite à la prise en compte d’autres développements (SCF, 2003).

Often in the early phases the available quantity of the product is relatively limited.
Often in the early phases the available quantity of the product is relatively limited.

which is consulted e.g. in cases of non-availability of medicines) ●● The administrative checking and monitoring of sampling (medicines and health products)
which is consulted e.g. in cases of non-availability of medicines) ●● The administrative checking and monitoring of sampling (medicines and health products)